O-ACETYLSERIN FOR USE IN THE PREVENTION AND TREATMENT OF GLUCOSE INTOLERANCE AND ASSOCIATED DISEASES
Patent Information
- Application Number
- DE602021022937
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-10-07
- Filing Date
- 2021-10-07
- Publication Date
- 2024-12-04
- Estimated Expiration
- 2041-10-07
AI Technical Summary
Current treatments for glucose intolerance and type 2 diabetes, such as lifestyle adjustments and medications like Metformin, are often insufficient or associated with adverse effects, and there is a need for new compounds and compositions that are safe for children and adolescents to effectively control glucose homeostasis and prevent the progression to type 2 diabetes.
The use of O-acetylserine, a synthetic metabolite derived from bacterial strains like Streptococcus salivarius, to treat and prevent glucose intolerance and associated diseases, including type 2 diabetes, either alone or in combination with other active ingredients in various formulations like powders, food products, or pharmaceuticals.
O-acetylserine demonstrates a protective effect on glucose homeostasis, reducing glucose intolerance induced by obesogenic diets and effectively preventing the onset of type 2 diabetes, as shown in mouse models, with potential for safer administration to children and adolescents.
Description
Technical field
[0001] The present invention relates to the field of prevention and / or treatment of metabolic disorders such as glucose intolerance or prediabetes, as well as diseases linked to glucose intolerance, such as Type 2 Diabetes. Prior art
[0002] Type 2 diabetes (T2D) is a disease characterized by chronic hyperglycemia, resulting from the body's inadequate use of insulin. This disease is usually the result of excess weight and physical inactivity, such as obesity, which develops in response to nutritional and lifestyle changes. Thus, risk factors associated with T2D include: overweight, advanced age, poor diet and excess calories or poor nutrition, physical inactivity, smoking, or family history (Vazquez et al. Comparison of body mass index, waist circumference, and waist / hip ratio in predicting incident diabetes: a meta-analysis. Epidemiol Rev 2007; 29: 115-28; Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.Lancet Diabetes Endocrinol 2015; 3: 866-75).
[0003] T2D is the most common type of diabetes in the world, accounting for 90% of all cases (World Health Organization. 1999. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus). Diabetes is a real public health problem due to its global prevalence, which doubled between 1980 and 2014, rising from 4.7 to 8.5% of the adult population (World Diabetes Report, World Health Organization 2016, ISBN: 9789242565256), the high cost of treatment, and its complications. Indeed, diabetes, in the long term, can affect the heart, blood vessels, eyes, kidneys, and nerves, and increase the risk of heart disease and myocardial infarction. Therefore, preventing and treating T2D is a highly relevant field of therapeutic investigation with strong economic and societal stakes (IDF Diabetes Atlas - 5th Edition, 2017).
[0004] Nowadays, recommendations for hygiene and dietary measures target prediabetes and, although rarely prescribed, preventive treatments are recommended for people at high risk of developing type 2 diabetes. Prediabetes, the early and reversible phase of diabetes, is characterized, in particular, by glucose intolerance.
[0005] Glucose intolerance is a risk factor for type 2 diabetes, which develops in the prediabetes phase. Glucose intolerance, or prediabetes or intermediate hyperglycemia, is a blood sugar disorder. An individual with glucose intolerance has blood sugar levels above normal but not high enough to diagnose diabetes. Glucose intolerance can be characterized by detecting decreased insulin sensitivity or increased insulin resistance. Prediabetes is a phase during which it is often still possible to reverse the diabetic trend to return blood sugar levels to normal. This precursor state of type 2 diabetes can, in some cases, be reversible with physical exercise and dietary adjustments.
[0006] Generally speaking, physical activity combined with a balanced diet can help lower blood glucose and prevent progression to T2D. However, the projected increase in type 2 diabetes cases in the coming years suggests that these lifestyle adjustments are not sufficient. Thus, it appears that rebalancing lifestyle habits is often unrealistic or insufficient and may be combined with prescribed oral medication to control blood glucose levels. However, these medications are few in number and some are not recommended for children and adolescents, who are increasingly developing glucose intolerance. For example, Metformin, generally used to treat T2D, may be prescribed. In addition, contraindications and unwanted side effects exist, such as nausea, vomiting, diarrhea, abdominal pain, or loss of appetite.These adverse effects are the cause of frequent treatment discontinuations (McGovern et al. Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta-analysis. Diabetes Obesity and Metabolism, 2017, 20(4):1040-1043). Long-term metformin treatment is associated with an increased risk of vitamin B6 and B12 deficiencies, which may be accompanied by neurological complications (Porter et al. Hyperglycemia and Metformin Use Are Associated With B Vitamin Deficiency and Cognitive Dysfunction in Older Adults. J. Clin. Endocrinol. Metab., 2019, 104(10): 4837-4847).
[0007] Targeting the reversible prediabetic state, and in particular glucose intolerance, early on therefore appears to be essential to prevent its progression to type 2 diabetes.
[0008] There is a need for novel compounds or compositions to control glucose homeostasis. There is also a need for novel compounds or compositions to target glucose intolerance.
[0009] There is a need for new compounds or compositions whose safety may be suitable for administration in children or adolescents.
[0010] There is a need for new treatments to prevent and / or treat impaired glucose tolerance. There is also a need for new treatments to prevent and / or treat diseases associated with or resulting from impaired glucose tolerance, such as, in particular, type 2 diabetes. Thus, there is a need for new compounds or compositions to prevent and / or treat prediabetes.
[0011] There is thus also a need to prevent and / or treat postprandial hyperglycemia. There is a need to treat and / or prevent diseases associated with glucose intolerance, in particular type 2 diabetes.
[0012] The present invention aims to satisfy all or part of these needs. Statement of the invention
[0013] The present invention provides a synthetic metabolite, O-acetylserine, for use in the treatment and / or prevention of glucose intolerance. It also provides O-acetylserine for use in the treatment and / or prevention of one or more diseases related to glucose intolerance, and in particular Type 2 Diabetes. Summary of the invention
[0014] The objective of the present invention is to provide novel substances for their use in a therapeutic method for preventing and / or treating glucose intolerance and / or a disease associated with glucose intolerance in an individual.
[0015] Surprisingly, the inventors observed a protective effect of O-acetylserine (or OAS) on glucose homeostasis. OAS limits the onset of glucose intolerance induced by obesogenic diets (high in fat or sugar) and which precedes the onset of T2D. The prevention and treatment of glucose intolerance thus allows the prevention and treatment of T2D.
[0016] Thus, according to a first aspect, the invention relates to O-acetylserine, or one of its salts for its use in the treatment and / or prevention of glucose intolerance and / or one or more diseases associated with glucose intolerance in an individual.
[0017] In a particular embodiment, the disease associated with glucose intolerance is type 2 diabetes.
[0018] Additionally, the individual may be overweight or obese.
[0019] In a particular embodiment, O-acetylserine is a synthetic metabolite of bacteria, in particular is a synthetic metabolite of bacteria of the intestinal microbiota, more particularly is a synthetic metabolite of the bacterial strain Streptococcus salivarius.
[0020] According to a second aspect, the invention relates to a composition for use in the treatment and / or prevention of glucose intolerance and / or one or more diseases associated with glucose intolerance in an individual comprising an O-acetylserine, or one of its salts and a physiologically acceptable carrier.
[0021] In a particular embodiment, the disease associated with glucose intolerance is type 2 diabetes.
[0022] In addition, the individual may be obese.
[0023] According to one embodiment, O-acetylserine is a synthetic metabolite of bacteria, in particular is a synthetic metabolite of bacteria of the intestinal microbiota, more particularly is a synthetic metabolite of the bacterial strain Streptococcus salivarius.
[0024] According to the invention, the composition may be a composition for oral administration, in particular in the form of a powder, granules, a food product, a drink, a pharmaceutical product, a nutraceutical, a food additive, a food supplement, a capsule or a gelcap.
[0025] In a particular embodiment, the composition further comprises an additional active ingredient, in particular chosen from metabolites, antioxidants, fish oils, DHA, EPA, vitamins, minerals, phytonutrients, a protein, a lipid, probiotics, additional active ingredients for preventing and / or treating glucose intolerance, and combinations thereof. Brief description of the drawings
[0026] [ Fig 1] represents the final body weight (left) and epididymal adipose tissue weight of the groups of mice studied after 12 weeks of diet and treatment: the control group receiving a control diet, the HFD group receiving an untreated high-fat diet (HFD), and the HFD group treated with O-acetylserine (HFD+OAS). The left diagram represents the average weight of the mice in each group in grams (ordinates). The groups of mice, from left to right, are indicated on the x-axis: Control; HFD and HFD+OAS. The difference in weight between the control group and the HFD group is statistically significant (* p<0.05).
[0027] The figure on the right represents the average epididymal adipose tissue weight of mice in each group in grams (ordinate). The mouse groups, from left to right, are indicated on the x-axis: Control; HFD; and HFD+OAS. The difference in epididymal adipose tissue weight between the control group and the HFD group or the HFD+OAS group is statistically significant (**** p<0.0001).
[0028] [ Fig 2] represents the results of the glucose tolerance test after 5 weeks of study for each of the groups of mice studied: the control group receiving a control diet, the HFD group receiving an untreated high-fat diet (HFD), and the HFD group treated with O-acetylserine (HFD+OAS). On the left, the curves represent the variation of the mean glucose concentration in the plasma of the mice in mg / dl (ordinates) as a function of time in minutes (abscissas) for each of the groups of mice after an oral glucose load. The control group is represented by the curve including the symbol o, the HFD group is represented by the curve with the symbol ● and the HFD+OAS group is represented by the curve with the symbol ■. The difference between the control group on the one hand and the HFD and HFD+OAS groups on the other hand is significant (with, respectively ****p<0.0001, ***p<0.001, **p<0.01 and *p<0.05 at t=15mn and at t=30mn, at t=60mn, at t=90mn and at t=120mn).
[0029] On the right, the columns represent the area under the curve in mg / dl / min (ordinates) from the curves in the left diagram for each of the groups of mice indicated, from left to right, on the x-axis: Control; HFD and HFD+OAS. The difference in the area under the curve between the control group on one side and the HFD and HFD+OAS groups on the other side is significant (****p<0.0001).
[0030] [ Fig 3] represents the results of the glucose tolerance test after 9 weeks of study for each of the groups of mice studied: the control group receiving a control diet, the HFD group receiving an untreated high-fat diet (HFD), and the HFD group treated with O-acetylserine (HFD+OAS). On the left, the curves represent the variation of the mean glucose concentration in the plasma of the mice in mg / dl (ordinates) as a function of time in minutes (abscissas) for each of the groups of mice after an oral glucose load. The control group is represented by the curve including the symbol o, the HFD group is represented by the curve with the symbol • and the HFD+OAS group is represented by the curve with the symbol ■. The difference between the control group on the one hand and the HFD and HFD+OAS groups on the other hand is significant (with, respectively ****p<0.0001, ***p<0.001, **p<0.01, and *p<0.05 at t=15mn, at t=30mn, at t=60mn, and at t=90mn). From t=60mn, the difference between the control group on one side and the HFD+OAS group on the other side is no longer significant and at t=30mn, the difference between the HFD group on one side and the HFD+OAS group on the other side is significant $$$$< p<0.0001.
[0031] On the right, the columns represent the area under the curve in mg / dl / min (ordinates) from the curves in the left diagram for each of the groups of mice indicated, from left to right, on the x-axis: Control; HFD and HFD+OAS. The difference in the area under the curve between each of the groups of mice is significant (****p<0.0001 between the control group and the HFD group, *p<0.05 between the HFD group and the HFD+OAS group and *p<0.05 between the control group and the HFD+OAS group).
[0032] [ Fig 4] represents the results of the glucose tolerance test after 5 days of study for each of the groups of mice studied: the control group received a conventional diet and did not receive O-acetylserine, while the OAS group also received a conventional diet as well as a daily dose of O-acetylserine (OAS).
[0033] On the left, the curves represent the variation of the mean glucose concentration in the plasma of the mice in mg / dL (ordinates) as a function of time in minutes (abscissas) for each of the groups of mice after an oral glucose load at t0. The control group is represented by the curve including the symbol ■, the OAS group is represented by the curve with the symbol •. The difference between the control group and the OAS group is significant (with, respectively ****p<0.0001 and *p<0.05 at t=15mn, at t=30mn and at t=60mn).
[0034] On the right, the columns represent the area under the curve in mg / dL / min (ordinates) from the curves in the left diagram for each of the groups of mice indicated, from left to right, on the x-axis: Control; OAS. The difference in the area under the curve between each of the groups of mice is significant (****p<0.0001).
[0035] [ Fig 5 ] represents the results of the glucose tolerance test after receipt for each of the groups of mice studied of an oral glucose load: the control group received only the oral glucose load at t0, while the OAS group received a dose of O-acetylserine (OAS) at the same time as the oral glucose load at t0.
[0036] On the left, the curves represent the variation of the mean glucose concentration in the plasma of the mice in mg / dL (ordinates) as a function of time in minutes (abscissas) for each of the groups of mice after an oral glucose load at t0. The control group is represented by the curve including the symbol ■, the OAS group is represented by the curve with the symbol •. The difference between the control group and the OAS group is significant (with ***p<0.001 at t=15mn).
[0037] On the right, the columns represent the area under the curve in mg / dL / min (ordinates) from the curves in the left diagram for each of the groups of mice indicated, from left to right, on the x-axis: Control; OAS. The difference in the area under the curve between each of the groups of mice is significant (*p<0.05). Detailed description
[0038] The inventors have conducted extensive work to identify the ability of O-acetylserine to treat and / or prevent glucose intolerance and / or a disease associated with glucose intolerance in an individual in need thereof. In particular, the inventors have demonstrated the ability of OAS to treat and / or prevent glucose intolerance in mice.
[0039] Indeed, as developed in the experimental section below, the inventors have demonstrated that treatment with OAS makes it possible to regulate glucose metabolism, notably with an improvement in glucose intolerance, in particular glucose intolerance associated with obesity, in a mouse model subjected to an obesogenic diet. They have thus demonstrated the usefulness of OAS in improving in vivo metabolic disorders, particularly caused by obesity. Definitions
[0040] The terms used in this specification are used with their usual meaning in the technical field considered, and with regard to the context of the specification in which the terms are used. Certain terms are further discussed below, or elsewhere in the specification, to provide additional guidance with regard to the invention and its practice. The following definitions are provided for the specification and claims.
[0041] The description of the various embodiments of the invention includes embodiments including " including ", " having ", " consisting of " And " consisting essentially of ". The words " to have " And " to understand ", or variations such as " a ", " have ", " understand " Or " including» should be understood to imply the inclusion of the element(s) indicated (such as an element of a composition or a method step) but not the exclusion of other elements. The term “consisting of” implies the inclusion of the element(s) indicated, to the exclusion of any additional elements. The expression “ consisting essentially of » implies the inclusion of the indicated elements, and possibly other elements where the other elements do not materially affect the fundamental and novel characteristics of the invention. Depending on the context, the term “comprise” may also strictly indicate the indicated characteristics, the indicated integers, the indicated steps or components and, therefore, in this case, it may be replaced by “consist of”.
[0042] By " type 2 diabetes " Or " DT2", is a chronic disease that occurs when the pancreas does not produce enough insulin (a hormone that regulates blood sugar), or when the body is unable to effectively use the insulin it produces. T2D is usually preceded by glucose intolerance.
[0043] The terms " approximately " Or " approximately" as used herein with respect to a numerical value refers to the usual error range for the value under consideration, as customarily identified by those skilled in the relevant technical field. The mention of the term "about" with respect to a specific value or parameter includes and describes as such that value or parameter. The term "about" refers to ± 10% of a given value. However, whenever the value in question refers to an indivisible object that would lose its identity when subdivided, then "about" refers to ± 1 of the indivisible object.
[0044] The term " individual " Or " patient" as used herein refers in particular to a mammal. Mammals considered include, but are not limited to, domestic animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-humans), rabbits, and rodents (e.g., mice and rats). In a particular embodiment, an individual, or patient, is a human being. By " glucose intolerance » is understood to refer to a pathophysiological state in which an individual's blood sugar is higher than normal but lower than the diagnostic threshold for type 2 diabetes. Glucose intolerance can be detected by measuring fasting blood sugar and by monitoring blood sugar during an oral glucose tolerance test (or OGTT test).
[0045] By " obesity", is intended to designate a pathophysiological condition in which an individual presents, in particular, an excess of adipose tissue, generally induced by an obesogenic diet, including, in particular, excessive consumption of high-calorie foods, genetic predispositions or insufficient or non-existent sports practice. An individual declared as obese has a body mass index (BMI) greater than 30. The body mass index, according to an official definition of the World Health Organization (WHO), is the indicator of health risks associated with excessive weight and underweight. BMI is calculated by dividing the individual's weight (in kilograms) by their height (in meters) squared. A BMI value is associated with a specific body type according to the classification given by the WHO.
[0046] Unlike an individual, obese ", we mean by a " overweight individual» an individual whose condition is not pathophysiological. An overweight individual often also has excess adipose tissue. An individual is generally considered overweight when they have a body mass index (BMI) between 25 and 30.
[0047] By " prediabetes ", is intended to designate a pathophysiological state characterized, in particular, by a high blood sugar level compared to normal, but below the threshold for defining type 2 diabetes. A fasting blood sugar level is considered to be (i) normal between 0.70 and 1.10 g / l, (ii) a sign of prediabetes between 1.10 and 1.25 g / l and (iii) a sign of diabetes when > 1.25 g / l. Prediabetes does not generally induce symptoms, but is often associated with obesity, dyslipidemia, and hypertension. It is a risk factor for cardiovascular diseases. Prediabetes is characterized, in particular, by glucose intolerance. In the context of the present invention, the terms " prevent ", " prevention " And " slow down the progression of» (and variations of these expressions) with respect to a physiological disorder or disease relates to the prophylactic treatment of the disease or disorder, for example in an individual suspected of having that disease or disorder, or being at risk of developing that disease or disorder. Preventing includes, but is not limited to, preventing or slowing the development of the disease, and / or maintaining one or more disease symptoms at a desired or lesser level. The term “preventing” does not require 100% elimination of the possibility or probability of the disease or disorder occurring. Rather, it refers to reducing to a lesser degree the risk or probability of occurrence of a given phenomenon, i.e., in the present invention, impaired glucose tolerance or a disease associated with impaired glucose tolerance, such as a prediabetic condition or type 2 diabetes.As noted, prevention can be complete, meaning the absence of symptoms or detectable disease, or partial, such that there are fewer symptoms or the symptoms are of lesser intensity.
[0048] By " glucose homeostasis ", we mean the glycemic balance of an individual characteristic of normal blood sugar. Normal fasting blood sugar balance in humans is between approximately 0.70 g / L and approximately 1.10 g / L (or between 70 mg / dL and 110 mg / dL). A blood sugar level below 0.70 g / L characterizes hypoglycemia while a blood sugar level above 1.10 g / L but below 1.26 g / L characterizes moderate hyperglycemia which may indicate glucose intolerance.
[0049] By " O-acetylserine salt", means an O-acetylserine salt prepared with physiologically acceptable acids or bases. However, acids or bases useful, for example, for the purification or isolation of OAS may also be used. As an O-acetylserine salt, mention may be made of O-acetyl-L-serine hydrochloride.
[0050] By " O-acetylserine derivative", means a physiologically acceptable O-acetylserine which has undergone one or more modifications, such as substitutions or intramolecular migrations. As an illustration of a modification, and in particular a substitution, of an O-acetylserine derivative may be mentioned the substitution of at least one of the hydrogens of the amine group of the OAS to form an amide function. As an illustration, a modification, and in particular an additional or alternative substitution, of an O-acetylserine derivative may be the substitution of the methyl group of the OAS by an alkyl group, in particular by a (C 1 -C 6 )alkyl, the alkyl group being optionally substituted, in particular with a halogen, in particular chosen from F and Cl.By way of illustration, a modification, and in particular an additional or alternative substitution, of an O-acetylserine derivative may be the substitution of the proton of the carboxyl group -COOH of OAS to form an ester function. OAS derivatives are OAS which exhibit the same activity, in particular the same activity for preventing and / or treating glucose intolerance and / or a disease associated with glucose intolerance in an individual, as OAS. As an O-acetylserine derivative, mention may be made of N-acetylserine.
[0051] As used herein, the terms " therapeutically effective amount " And " prophylactically effective amount» refer to an amount that provides a therapeutic benefit in the treatment, prevention, or management of the disease processes under consideration. The specific amount that is therapeutically effective can be readily determined by a physician and may vary depending on factors such as the type and stage of the disease processes under consideration, medical history, patient gender, weight, and age, diet, and the administration of other therapeutic agents.
[0052] For the purposes of the invention, “ significantly » used in the context of a change, means that the observed change is notable or has statistical significance.
[0053] For the purposes of the invention, the expressions “ substantially similar ", " substantially not different ", " substantially similar " Or " not significantly different» (or any other variation) used in connection with a feature of the invention is intended to define a set of embodiments of the invention related to that feature that are largely but not entirely identical to embodiments including that feature.
[0054] By " oral glucose tolerance test " Or " OGTT test ", is intended to designate a test for measuring the body's ability to use glucose. An OGTT test is well known to those skilled in the art. For example, the protocol described in Nagy et al., Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT), can be used. J. Vis. Exp. (131), e56672, doi: 10.3791 / 56672 (2018).
[0055] For the purposes of the invention, the terms “ to treat ", " treatment ", " therapy " Or " therapeutic» refer to the administration or consumption of an active ingredient, O-acetylserine or any of its salts or derivatives, or a composition comprising such an active ingredient for the purpose of curing, alleviating, reducing, mitigating, or ameliorating a disease or pathological disorder, or one or more associated symptoms, or to prevent or slow the progression of such symptom(s) or disease, or to arrest the development of such symptom(s), or disease or pathological disorder in a statistically significant manner. More particularly, “treat” or “treatment” includes any approach to achieve a beneficial effect or desired outcome with respect to a condition of impaired glucose tolerance in an individual. Beneficial or desired clinical outcomes may include, but are not limited to, mitigating or ameliorating impaired glucose tolerance, a disease associated with impaired glucose tolerance,such as prediabetes or type 2 diabetes, or one or more symptoms of such a disease; the reduction or reduction of the extent of impaired glucose tolerance, a disease associated with impaired glucose tolerance, or one or more symptoms of such a disease; the stabilization, i.e., the absence of worsening, of impaired glucose tolerance, a disease associated with impaired glucose tolerance, or one or more symptoms of such a disease; the prevention of impaired glucose tolerance, a disease associated with impaired glucose tolerance, or one or more symptoms of such a disease; the prevention of the spread of impaired glucose tolerance, or one or more symptoms of such a disease; the slowing down of impaired glucose tolerance,or one or more symptoms of such a disease or the progression of one or more symptoms of such a disease; decreasing the recurrence of glucose intolerance, a disease associated with glucose intolerance, or one or more symptoms of such a disease; and interrupting glucose intolerance, a disease associated with glucose intolerance, or one or more symptoms of such a disease. In other words, "treatment" as used herein includes any cure, improvement, reduction, or interruption of glucose intolerance, a disease associated with glucose intolerance, or one or more symptoms of such a disease. A ", reduction » of a symptom or disease means a decrease in the severity or frequency of the disease or symptom, or the elimination of the disease or symptom. As used in this specification and the claims, the singular forms " A ", " a ", " le " And " la » include plurality, unless otherwise explicitly indicated by the context. The expression " physiologically acceptable vehicle » is intended to designate any substance or composition compatible with the organism of the individual to whom an active ingredient of the invention is to be administered. In particular, a physiologically acceptable vehicle is a substance or composition whose administration to an individual is not accompanied by significant deleterious effects. It may be, for example, a non-toxic solvent such as water or an aqueous saline solution. In particular, such a vehicle is compatible with oral or rectal administration, and preferably is suitable for administration by the oral route.
[0056] The list of sources, ingredients and components set forth below are understood to be described such that any combinations and mixtures thereof are also contemplated within the scope of the present invention.
[0057] It is understood that each maximum numerical limitation given in the description includes each lower numerical limitation, as if such lower numerical limitations were expressly written therein. Each minimum numerical limitation given in this description includes every upper numerical limitation, as if such upper numerical limitations were expressly written therein. Each numerical range given throughout the description includes each narrower numerical range included within such wider numerical range, as if such narrower numerical ranges were all expressly written therein.
[0058] All lists given in the description, such as, for example, lists of ingredients, are intended and should be interpreted as Markush groups. Thus, all lists can be read and interpreted as elements "selected from the group consisting of" ... list of elements ... "and their combinations and mixtures".
[0059] Reference may be made hereinafter to trade names of components comprising various ingredients used in this specification. The inventors do not intend to be limited to materials under a particular trade name. Equivalent materials (e.g., those obtained from a different source under a different name or reference number) to those indicated herein by a trade name may be substituted and used in the specification herein. O-acetylserine
[0060] The present invention relates to O-acetylserine (OAS), or a salt thereof for use in the treatment and / or prevention of glucose intolerance in an individual. It also relates to OAS, or a salt thereof for use in the treatment and / or prevention of one or more diseases associated with glucose intolerance in an individual.
[0061] In particular, the present invention relates to O-acetylserine (OAS), or a salt thereof, for use in the treatment and / or prevention of glucose intolerance in an individual. It also relates to OAS, or a salt thereof), for use in the treatment and / or prevention of one or more diseases associated with glucose intolerance in an individual.
[0062] O-acetylserine (C 5 H 9 NO 4 ) is a secondary intracellular metabolite of sulfur amino acid metabolism in some bacteria and plants with the following formula:
[0063] It is a non-proteinogenic α-amino acid derived from serine by acetylation from acetyl-CoA by serine O-acetyltransferase. It is an intermediate in cysteine biosynthesis in bacteria and plants, which convert it to cysteine by cysteine synthase.
[0064] The inventors identified OAS in a culture supernatant fraction of a strain of Streptococcus salivarius by mass spectrometry analyses.
[0065] This commensal species is present in dominance in the oral cavity and in subdominance in the human digestive tract. Strains of S. salivarius are able to synthesize OAS.
[0066] OAS is also present in various plants.
[0067] In humans, this molecule is found in the prostate, urine and blood and is of bacterial (particularly intestinal microbiota bacteria) and dietary origin. OAS is referenced HMDB0003011 in the HMDB 4.0 human metabolite database (http: / / www.hmdb.ca / metabolites / HMDB0003011) and corresponds to CAS number 5147-00-2.
[0068] The O-acetylserine according to the invention may also be in the form of OAS salt. In particular, the OAS may be in the form of O-acetyl-L-serine hydrochloride (OAS.HCl). The OAS.HCl salt (C 5 H 9 NO 4 .HCl) is referenced with the CAS number 66638-22-0.
[0069] O-acetylserine can also be found as an OAS derivative or as an OAS derivative salt.
[0070] In particular, OAS may be in the form of N-acetylserine (NAS). OAS may also be in the form of a NAS salt.
[0071] An OAS suitable according to the invention is notably sold as a chemical product under the commercial reference A6262_SIGMA ®< by the company Sigma-Aldrich.
[0072] A derivative of OAS, and in particular N-acetylserine, is notably sold as a chemical product under the commercial reference A2638 ®< by the company Sigma-Aldrich.
[0073] According to a particular embodiment, the O-acetylserine according to the invention is a synthetic metabolite of bacteria, in particular is a synthetic metabolite of bacteria of the intestinal microbiota, more particularly is a synthetic metabolite of the bacterial strain Streptococcus salivarius.
[0074] In some embodiments, OAS or a salt thereof may be included in a composition. Composition
[0075] The present invention further relates to a composition for use in the treatment and / or prevention of glucose intolerance and / or one or more diseases associated with glucose intolerance in an individual comprising O-acetylserine according to the invention, or one of its salts and at least one physiologically acceptable carrier.
[0076] A composition as described is administered to an individual in need thereof in a therapeutically effective amount. This amount is determined based on the characteristics of each individual by healthcare professionals.
[0077] In some embodiments, the composition is suitable for administration during or outside of meals, preferably outside of a meal. In some embodiments, the composition may be suitable for administration in at least one daily dose, in particular in a single daily dose.
[0078] In some embodiments, a composition may be administered each day consecutively over the administration period. Alternatively, a composition may be administered over a period of one, two, or more consecutive days followed by a break period of at least one, two, or more consecutive days. The administration and break periods may constitute a cycle. Administration of a composition may be over at least one, or two, three, or more consecutive cycles.
[0079] A composition may be administered for a period of at least five weeks, or at least six weeks, or at least seven weeks, or at least eight weeks, or at least nine weeks.
[0080] A composition may be administered for at least two consecutive days, in particular for at least five consecutive days, over an interval of one week, and over a period of at least one to at least twelve weeks, in particular from at least one to at least ten weeks, in particular from at least two to at least five weeks, and in particular for at least three weeks.
[0081] In some embodiments, a composition may be administered for at least two consecutive days over a one-week interval, particularly for at least five consecutive days over a one-week interval.
[0082] As a physiologically acceptable vehicle that can be used to formulate a composition of the invention, mention may be made, in a non-limiting manner, of water, saline buffers, in particular a phosphate buffer, sodium bicarbonate, juices, dairy products, in particular milk or yogurts, infant food compositions, thickening agents, such as glycerol monostearate, sweetening agents, coating agents, such as rapeseed oil; soybean oil; peanut oil; soy lecithin or fish gelatin, diluting agents, such as lactose; lactose monohydrate or starch, binders, such as povidone; gelatinized starch; gums; sucrose;polyethylene glycol (PEG) 4000 or PEG 6000, dispersing agents, such as microcrystalline cellulose or sodium carboxymethyl starch, such as sodium carboxymethyl starch type A, lubricating agents, such as magnesium stearate, flow-forming agents, such as anhydrous colloidal silica, etc.;
[0083] A physiologically acceptable carrier may be any substance used for the preparation of pharmaceutical dosage forms, including coating materials, film-forming materials, fillers, disintegrating agents, release-modifying materials, carrier materials, diluents, binding agents, and other adjuvants. Typical physiologically acceptable carriers include substances such as sucrose, mannitol, sorbitol, starch and starch derivatives, lactose, lubricating agents such as magnesium stearate, disintegrating agents, and buffering agents.Also, suitable physiologically acceptable carriers include, for example, water, saline solutions, alcohols, oils, preferably vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, surfactants, perfume oil, fatty acid, monoglycerides and diglycerides, hydroxymethylcellulose, polyvinylpyrrolidone and the like. The pharmaceutical compositions may include auxiliary agents, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorants, flavorings and / or aromatic substances.
[0084] Liquid forms are contemplated for the present invention. These may include emulsions, solutions, suspensions, and syrups. Solid forms are also contemplated, such as suppositories, tablets, lozenges, pills, capsules, powders, effervescent formulations, dragees, granules, or capsules.
[0085] A composition according to the invention may further comprise any additive or excipient usually used in the field with regard to the use considered for the composition. Thus, a composition of the invention may further comprise at least one chosen from a sweetener, a stabilizer, an antioxidant, an additive, a flavoring agent and / or a coloring agent. The formulation of a composition of the invention is carried out using the usual methods used in the field, in particular for producing coated tablets, capsules, gels, hydrogels for controlled release, emulsions, foams, syrups, liquids, tablets, capsules, or suppositories.
[0086] The present composition may be adapted for oral, sublingual, nasal or rectal administration, in particular oral administration.
[0087] In one embodiment, the composition may be in the form of a dietary supplement, a beverage supplement, a nutritional product, a medical food, or a nutraceutical composition.
[0088] A composition may also be in the form of a nutritional or nutraceutical composition.
[0089] In particular, a composition may be a food supplement.
[0090] A food supplement may be presented in the form of capsules, softgels, tablets, coated tablets, pills, pastes, lozenges, gums, oral solutions or emulsions, syrup or gel.
[0091] A composition suitable for the invention may in particular be formulated in the form of a food supplement chosen from dairy products, dairy drinks, yogurts, fruit or vegetable juices or their concentrates, powders, soy or cereal-based drinks, breakfast cereals such as muesli flakes, fruit and vegetable juice powders, cereal and / or chocolate bars, confectionery, spreads, milk flours, smoothies, ice creams, reconstituted fruit products, food bars, sauces, sports supplements, including dairy and non-dairy sports supplements, a dessert, a frozen food, a soup, a liquid suspension, a tablet, a gum or a candy.
[0092] Advantageously, a composition according to the present invention, intended for oral administration, may be provided with a coating resistant to gastric juice, in order to ensure that the O-acetylserine of the invention included in said composition can pass through the stomach without being damaged. The release of the OAS according to the invention can thus occur for the first time in the upper intestinal tract.
[0093] According to a particular embodiment, an oral composition suitable for the invention may be chosen from a powder, granules, a food product, a drink, a pharmaceutical product, a nutraceutical, a food additive, a food supplement, a capsule, and a gel capsule.
[0094] In another embodiment of the invention, a composition may be administered rectally. In particular, a composition for rectal administration may be prepared in the form of a suppository, an enema, or a foam.
[0095] In one embodiment, a composition may further comprise at least one additional active selected from: metabolites, antioxidants, fish oils, DHA, EPA, vitamins, minerals, phytonutrients, a protein, a lipid, probiotics and combinations thereof.
[0096] As probiotic active ingredients that can be used additionally, we can cite strains of probiotic bacteria from Streptococcus, Lactobacillus, Lactococcus, Bifidobacterium, Veillonella, Desemzia, Coprococcus, Collinsella, Citrobacter, Turicibacter, Sutterella, Subdoligranulum, Sporobacter, Sporacetigenium, Ruminococcus, Roseburia, Proteus, Propionobacterium, Leuconostoc, Weissella, Pediococcus, Prevotella, Parabacteroides, Papillibacter, Oscillospira, Melissococcus, Dorea, Dialister, Clostridium, Cedecea, Catenibacterium, Butyrivibrio, Buttiauxella, Bulleidia, Bilophila, Bacteroides, Anaerovorax, Anaerostopes, Anaerofilum, Enterobacteriaceae, Fermicutes, Atopobium, Alistipes, Acinetobacter, Slackie, Shigella, Shewanella, Serratia, Mahella, Lachnospira, Klebsiella, Idiomarina, Fusobacterium, Faecalibacterium, Eubacterium, Enterococcus, Enterobacter, Or Eggerthella.
[0097] As phytonutrients suitable for the invention, mention may be made of carotenoids, polyphenols or resveratrol. As antioxidants suitable for the invention, mention may be made of vitamin C, glutathione, caffeine, or tocopherol. As vitamins suitable for the invention, mention may be made of vitamins A, B, C, or D. As minerals, mention may be made of iron, magnesium, calcium, zinc, copper, or sodium.
[0098] In particular, the composition may comprise at least one additional active agent for preventing and / or treating glucose intolerance. Said at least one additional active agent for preventing and / or treating glucose intolerance is different from OAS, or one of its salts.
[0099] According to one embodiment, a composition according to the invention comprises O-acetylserine, or one of its salts, according to the invention, at least one physiologically acceptable vehicle, and at least one additional active agent making it possible to prevent and / or treat glucose intolerance.
[0100] In particular, the additional active ingredient can be any antidiabetic molecule, particularly metformin. Glucose intolerance can be treated with an alpha-glucosidase inhibitor (Acarbose, Voglibose), or a pancreatic lipase inhibitor (Orlistat), or a glinide (Nateglinide) or an incretin mimetic (Liraglutide).
[0101] Metformin (C 4 H 11 N 5 ) is an oral antidiabetic drug from the normoglycemic biguanide family used in the treatment of type 2 diabetes and recommended for prediabetic people at greatest risk of developing type 2 diabetes.
[0102] According to one aspect, the administration in the same composition of OAS, or one of its salts, and metformin makes it possible to reduce the quantity of metformin in the composition, compared to a composition comprising only metformin, while having an equivalent action on the prevention and / or treatment of glucose intolerance and / or a disease associated with glucose intolerance.
[0103] According to a particular embodiment, the composition is not a nutritional composition comprising a mixture of oligosaccharides consisting of an N-acetylated oligosaccharide, a galacto-oligosaccharide and a sialylated oligosaccharide.
[0104] According to another embodiment, a composition of the invention is not intended to be used for reducing and / or preventing excessive accumulation of body fat in an infant or young child, and / or for the prevention of a health disorder at a later age linked to excessive accumulation of body fat in an infant or young child, such as obesity at a later age, and associated comorbidities. Glucose intolerance and associated diseases
[0105] As indicated above, the OAS according to the invention, or one of its salts or a composition according to the invention, are used in a therapeutic method for preventing and / or treating glucose intolerance and / or one or more diseases associated with glucose intolerance in an individual.
[0106] An individual or patient considered according to the invention may be a mammal. A mammal targeted by the invention may be, for example, selected from domestic animals (such as cattle, sheep, cats, dogs, and horses, including cats and dogs, primates, such as human and non-human primates, rabbits, and rodents, such as mice and rats. According to one embodiment, an individual or patient targeted by the invention may be a human being.
[0107] OAS or one of its salts or a composition according to the invention may be particularly suitable for use in a therapeutic treatment to prevent and / or treat prediabetes, and / or a disease or disorder associated with prediabetes, or a symptom of prediabetes.
[0108] Glucose intolerance or prediabetes may be asymptomatic. However, they may be associated with obesity, dyslipidemia with high triglycerides and / or low HDL cholesterol, and hypertension. Glucose intolerance and prediabetes are associated with an increased risk of cardiovascular disease. Prediabetes and glucose intolerance are considered an early phase of type 2 diabetes. Glucose intolerance or prediabetes can be diagnosed by various methods known to those skilled in the art. In particular, glucose intolerance in humans is diagnosed based on two criteria: fasting blood glucose, and blood glucose two hours after oral ingestion of glucose.
[0109] Thus, impaired glucose tolerance can be diagnosed if: (i) fasting, blood glucose is: between 6.1 and 6.9 mmol / L (110-125 mg / dL) and if (ii) two hours after an ingestion of 75 g of oral glucose, blood glucose is between 7.8 mmol / L and 11.0 mmol / L (140 mg / dL and 199 mg / dL).
[0110] Blood glucose measurement two hours after glucose ingestion is performed by an oral glucose tolerance test or OGTT. Such a test is described in Hjellestad et al., HbA1c versus oral glucose tolerance test as a method to diagnose diabetes mellitus in vascular surgery patients, Cardiovascular Diabetology, 12:79 (2013).
[0111] Glucose intolerance or prediabetes can usually be followed by type 2 diabetes. Type 2 diabetes (or T2D) is a disease associated with glucose intolerance or prediabetes.
[0112] According to one embodiment, the OAS or one of its salts or its derivatives or a composition according to the invention may be particularly suitable for use in a therapeutic treatment to prevent and / or treat type 2 diabetes.
[0113] T2D can be diagnosed by various methods known to those skilled in the art. In particular, T2D can be diagnosed if one or more of the following criteria are met: fasting blood glucose, blood glucose two hours after oral glucose administration, or postprandial or random blood glucose glycated hemoglobin A1C (HbA1C).
[0114] Thus, T2D is diagnosed if the blood glucose is: (i) fasting, greater than or equal to 7.0 mmol / L (126 mg / dL), or if (ii) two hours after an ingestion of oral glucose of 75 g, greater than or equal to 11.1 mmol / L (200 mg / dL), or if (iii) the random plasma glucose is greater than 11.1 mmol / L (200 mg / dL) or if (iv) the glycated hemoglobin A1c (HbA1c) level is greater than or equal to 48 mmol / mol (equivalent to 6.5%).
[0115] According to one embodiment, the present invention also relates to a therapeutic treatment method for preventing and / or treating glucose intolerance and / or a disease associated with glucose intolerance in an individual in need thereof comprising at least one step of administering to said individual OAS or one of its salts or of administering to said individual a composition according to the invention.
[0116] According to one embodiment, the present invention also relates to a therapeutic treatment method for preventing and / or treating prediabetes and / or a disease associated with prediabetes in an individual in need thereof comprising at least one step of administering to said individual OAS or one of its salts, or of administering to said individual a composition according to the invention.
[0117] According to one embodiment, the present invention also relates to a therapeutic treatment method for preventing and / or treating type 2 diabetes in an individual in need thereof, comprising at least one step of administering to said individual OAS or one of its salts or of administering to said individual a composition according to the invention.
[0118] A method according to the invention may comprise, prior to the step of administering an active ingredient of the invention, a step of diagnosing glucose intolerance, prediabetes or type 2 diabetes. Such a diagnosis may be carried out by any diagnostic method known to those skilled in the art for this purpose, and in particular by one of the methods described above.
[0119] A method according to the invention may further comprise a step of observing the reduction, suppression, or improvement of a symptom or a glycemic marker of glucose intolerance, prediabetes or type 2 diabetes.
[0120] According to a particular embodiment, an individual or patient considered for the invention may be overweight or obese.
[0121] A use or method according to the invention may comprise administering to an individual or patient in need thereof OAS or one of its salts or a composition according to the invention by any route of administration that may be suitable. Examples include oral, sublingual, nasal, or rectal administration. Preferably, administration of OAS or one of its salts, or a composition according to the invention may be by oral route.
[0122] According to one embodiment, the OAS or one of its salts or the composition according to the invention can be administered in at least one daily dose, in particular two or three daily doses. More particularly, in at least one daily dose.
[0123] OAS or one of its salts or the composition according to the invention may be taken with or without meals. Over a 24-hour period, OAS or one of its salts or a composition according to the invention may be taken at any time. In particular, OAS or one of its salts or a composition according to the invention may be taken in the morning, and in particular with the morning meal.
[0124] In particular, the administration of OAS or one of its salts or of a composition according to the invention can be done outside of meals, in particular in a daily dose.
[0125] The period of time during which the OAS or one of its salts or a composition according to the invention is administered depends on several factors, such as the age, weight, sex of the patient, the presence of other pathological disorders, diet, and is adapted by those skilled in the art according to the usual practice in the field.
[0126] A suitable period of time for administration of OAS or one of its salts or a composition according to the invention may be at least five weeks, or at least six weeks, or at least seven weeks or at least eight weeks, or at least nine weeks.
[0127] During an administration period, the OAS or one of its salts or the composition according to the invention may be administered each day consecutively, or the administration may be carried out for periods of one or more days, followed by a period of interruption of one or more days, where appropriate followed by one or more cycles of administration and interruption.
[0128] According to certain embodiments, the OAS or one of its salts or the composition according to the invention can be administered over a period of one, two or more consecutive days followed by an interruption period of at least one, two or more consecutive days. The administration and interruption periods can constitute a cycle. The administration of OAS or one of its salts or a composition according to the invention can be carried out over at least one, or even two, three or more consecutive cycles.
[0129] Thus, the OAS or one of its salts or the composition according to the invention may be administered for at least two consecutive days over a one-week interval. According to one embodiment, the administration may be carried out for at least five consecutive days over a one-week interval. The administration may be continued over two, three or more weeks as indicated above.
[0130] According to one embodiment, the OAS or one of its salts or the composition according to the invention can be administered in an effective therapeutic amount or dose. In particular, the OAS or one of its salts or the composition according to the invention can be administered at a daily dose equivalent to a dose ranging from at least about 70 mg / kg / day to at least about 2000 mg / kg / day. In particular, a dose suitable for the invention can be from at least about 100 mg / kg / day to at least about 1000 mg / kg / day, and in particular from at least about 200 mg / kg / day to at least about 500 mg / kg / day.
[0131] According to another aspect, the invention also relates to the use of OAS or one of its salts or the composition according to the invention for the manufacture of a medicament. In particular, it relates to the use of OAS or one of its salts or the composition according to the invention for the manufacture of a medicament for preventing and / or treating glucose intolerance and / or one or more diseases associated with glucose intolerance.
[0132] It is intended that the invention encompasses all variations, combinations and permutations in which one or more limitations, features, clauses, descriptive terms, etc., of one or more of the claims listed below may be introduced into another claim dependent on the same base claim (or, as the case may be, any other claim), unless otherwise indicated or unless it would be obvious to a person skilled in the art that a contradiction or inconsistency would occur. Where items are presented in list form (e.g., in Markush group or similar format), it is to be understood that each subgroup of items is also disclosed, and any item may be deleted from the group. It is to be understood that in general, where the invention or aspects of the invention is / are designated as comprising items, features, etc., particular, certain embodiments of the invention or certain aspects of the invention consist of, or consist essentially of, such elements, features, etc. For simplicity, these embodiments have not always been specifically set forth in so many words. It is also to be understood that any embodiment or aspect of the invention may be explicitly excluded from the claims, regardless of whether the specific exclusion is mentioned in the specification. Publications and other documents cited to describe the background of the invention and to provide additional details concerning its practice are incorporated herein by reference.
[0133] The invention is described below in more detail by means of the following examples which are presented for illustration purposes only, and are not limiting of the invention.
[0134] The invention is described below in more detail by means of the following examples which are presented for illustration purposes only. Examples Example 1: preventive action of a traitement based on an act if invented by the individual
[0135] Seven-week-old male C57BL / 6JRj mice from Janvier Labs were fed a standard animal diet.
[0136] A first group of 10 mice, which did not receive OAS treatment, served as a control group.
[0137] A second group of 10 mice was treated with a daily dose of OAS of 1000 mg / kg for 5 days. The OAS used was the product marketed under the name A6262-SIGMA by the company Sigma-Aldrich (CAS No. 66638-22-0). This group is the OAS treatment group.
[0138] An oral glucose tolerance test (OGTT) was performed on each of the two groups of mice. This test consists of monitoring plasma glucose concentrations for 120 min, after the mice have received an oral glucose load. Thus, at T0 (fasting blood glucose), glucose (2.5g / kg) is given orally to the animal. A drop of blood is taken from the tail every 15 to 30 minutes for 90 minutes to measure blood glucose with a strip glucometer (Accu-Check Perfoma, available in pharmacies).
[0139] The OGTT was performed on the 5th day of treatment 2 h after the OAS treatment group received a dose of 500 mg / kg. At the time of the OGTT test, mice in the treatment group also received 500 mg / kg of OAS along with the oral glucose load.
[0140] The control group received only the oral glucose load.
[0141] Fasting blood glucose levels of animals tended to be lower in the OAS treatment group and blood glucose levels at 15min, 30min and 60min after the oral glucose load were significantly lower in the OAS treatment group compared to the control group.
[0142] The results of this test show that a 5-day treatment with OAS decreases the fasting blood glucose level of the treated group and significantly decreases hyperglycemia caused by an oral glucose load ( Figure 4 ).
[0143] This treatment significantly reduces hyperglycemia with a lower area under the curve than that of the control group ( Figure 4 ), demonstrating the effect of O-acetylserine on the regulation of postprandial hyperglycemia and thus the preventive action of an active ingredient according to the invention in the establishment of insulin resistance and / or prediabetes. Example 2: preventive action of a single dose of an active ingredient according to the invention on healthy individuals on postprandial blood sugar
[0144] Seven-week-old male C57BL / 6JRj mice from Janvier Labs were fed a standard animal diet.
[0145] A first group of 5 mice, which did not receive OAS treatment, served as a control group.
[0146] A second group of 5 mice was treated with a single dose of 1000 mg / kg of OAS. The OAS used was the product marketed under the name A6262_SIGMA by the company Sigma-Aldrich (CAS No. 66638-22-0). This group is the OAS treatment group.
[0147] An oral glucose tolerance test (OGTT) was performed on each of the two groups of mice. This test consists of monitoring plasma glucose concentrations for 120 min, after the mice have received an oral glucose load. Thus, at T0 (fasting blood glucose), glucose (2.5g / kg) is given orally to the animal. A drop of blood is taken from the tail every 30 minutes for 120 minutes to measure blood glucose levels with a strip glucometer (Accu-Check Perfoma, available in pharmacies).
[0148] In the OGTT, the OAS treatment group received a dose of 1000 mg / kg of OAS concurrently with the oral glucose load. The control group received only the oral glucose load. Blood glucose levels at 15 min after the oral glucose load were significantly lower in the OAS treatment group compared to the control group.
[0149] The results of this test show that after 15 minutes, a single dose of OAS significantly reduces hyperglycemia caused by an oral glucose load ( Figure 5 ). This treatment significantly reduces hyperglycemia with a lower area under the curve than that of the control group ( Figure 5 ). A single dose of O-acetylserine is capable of reducing postprandial hyperglycemia. This thus demonstrates the preventive action of a single dose of an active ingredient according to the invention in establishing insulin resistance and / or prediabetes. Example 3: action of the active ingredient according to the invention on HFD individuals
[0150] The action of an active ingredient according to the invention was also tested in individuals on an obesogenic diet.
[0151] Seven-week-old male C57BL / 6JRj mice from Janvier Labs were fed a high-fat diet (HFD, 45% fat and 20% sucrose) for 12 weeks. This diet is comparable to an obesogenic diet promoting glucose intolerance.
[0152] A first group of 10 mice receiving this diet was treated with a daily dose of OAS of 200 mg / kg / day, at a frequency of 5 days per week for the 12 weeks of the diet. The OAS used is the product marketed under the name A6262-SIGMA by the company Sigma-Aldrich (CAS No. 66638-22-0). This group is the HFD+OAS group.
[0153] The second group of 9 mice fed the HFD diet did not receive OAS treatment. This is the HFD group.
[0154] A final group of 9 mice, which did not receive any special diet or OAS treatment, served as a control group.
[0155] In mice on HFD diet, significantly higher weight gain (*p<0.05) and a significant increase in epididymal adiposity (****p<0.0001) were observed after 12 weeks of diet, compared to mice not fed HFD diet (control group). These characteristics are indicative of the onset of obesity in mice ( Figure 1 ).
[0156] An oral glucose tolerance test (OGTT) was performed on each of the three groups of mice. This test consists of monitoring plasma glucose concentrations for 120 min, after the mice have received an oral glucose load. Thus, at T 0 (fasting blood glucose), glucose (2g / kg) is given orally to the animal. A drop of blood is taken from the tail every 30 minutes for 120 minutes to measure blood glucose with a strip glucometer (Accu-Check Perfoma, available in pharmacies).
[0157] Glucose tolerance is a reflection of the body's ability to regulate the return to normal blood sugar levels after a glucose load.
[0158] The OGTT was performed at 5 weeks and 9 weeks after the start of the obesogenic diet. The results of this test show the onset of glucose intolerance as early as 5 weeks in the groups of mice fed the HFD diet. Treatment with OAS had no visible effect in the HFD + OAS group after 5 weeks ( Figure 2 ). However, after 9 weeks, this treatment significantly reduced glucose intolerance with an area under the curve similar to that of the control group ( Figure 3 ).
[0159] In conclusion, treatment with O-acetylserine helps to regulate in vivo glucose metabolism, including an improvement in glucose intolerance associated with an obesogenic diet.
Claims
1. O-Acetylserine, or one of its salts, for use thereof in the treatment and / or the prevention of glucose intolerance and / or one or more diseases associated with glucose intolerance in an individual.
2. O-Acetylserine for use thereof according to Claim 1, wherein the disease associated with glucose intolerance is type 2 diabetes.
3. O-Acetylserine for use thereof according to Claim 1 or 2, wherein the individual is overweight or obese.
4. O-Acetylserine for use thereof according to any one of the preceding claims, wherein the 0-acetylserine is a synthetic metabolite of bacteria, and in particular is a synthetic metabolite of bacteria of the intestinal microbiota.
5. O-Acetylserine for use thereof according to Claim 4, wherein the 0-acetylserine is a synthetic metabolite of the Streptococcus salivarius bacterial strain.
6. Composition for use thereof in the treatment and / or the prevention of glucose intolerance and / or one or more diseases associated with glucose intolerance in an individual, comprising an 0-acetylserine, or one of its salts, and a physiologically acceptable carrier.
7. Composition for use thereof according to Claim 6, wherein the disease associated with glucose intolerance is type 2 diabetes.
8. Composition for use thereof according to Claim 6 or 7, wherein the individual is obese.
9. Composition for use thereof according to any one of Claims 6 to 8, wherein the 0-acetylserine is a synthetic metabolite of bacteria, and in particular is a synthetic metabolite of bacteria of the intestinal microbiota.
10. Composition for use thereof according to Claim 9, wherein the 0-acetylserine is a synthetic metabolite of the Streptococcus salivarius bacterial strain.
11. Composition for use thereof according to any one of Claims 6 to 10, wherein the composition is an oral composition, in particular in the form of a powder, granules, a food product, a beverage, a pharmaceutical product, a nutraceutical, a food additive, a food supplement, a capsule or a gel capsule.
12. Composition for use thereof according to any one of Claims 6 to 11, wherein the composition additionally comprises an additional active ingredient, in particular chosen from metabolites, antioxidants, fish oils, DHA, EPA, vitamins, minerals, phytonutrients, a protein, a lipid, probiotics, additional active ingredients for preventing and / or treating glucose intolerance, and combinations of these.
